resTORbio begins Phase IIb mTORC1 inhibitors trial

US-based clinical-stage biopharmaceutical company PureTech Health subsidiary resTORbio has initiated a Phase IIb study of its mechanistic target of rapamycin complex 1 (mTORC1) programme.

Source: Drug Development Technology - May 9, 2017 Category: Pharmaceuticals Source Type: news